Cargando…

Development and validation of MMR prediction model based on simplified clinicopathological features and serum tumour markers

BACKGROUND: Although simplified clinicopathological features and serum tumour markers (STMs) were reported to be associated with the status of mismatch repair (MMR) in colorectal cancer (CRC) patients, their predictive value alone or in combination for MMR status remains unknown. METHODS: A retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yinghao, Peng, Tao, Li, Han, Yang, Ming, Wu, Liang, Zhou, Zili, Zhang, Xudan, Han, Shengbo, Bao, Haijun, Cai, Kailin, Zhao, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578682/
https://www.ncbi.nlm.nih.gov/pubmed/33096478
http://dx.doi.org/10.1016/j.ebiom.2020.103060
_version_ 1783598419700350976
author Cao, Yinghao
Peng, Tao
Li, Han
Yang, Ming
Wu, Liang
Zhou, Zili
Zhang, Xudan
Han, Shengbo
Bao, Haijun
Cai, Kailin
Zhao, Ning
author_facet Cao, Yinghao
Peng, Tao
Li, Han
Yang, Ming
Wu, Liang
Zhou, Zili
Zhang, Xudan
Han, Shengbo
Bao, Haijun
Cai, Kailin
Zhao, Ning
author_sort Cao, Yinghao
collection PubMed
description BACKGROUND: Although simplified clinicopathological features and serum tumour markers (STMs) were reported to be associated with the status of mismatch repair (MMR) in colorectal cancer (CRC) patients, their predictive value alone or in combination for MMR status remains unknown. METHODS: A retrospective analysis of 3274 participants with MMR testing and STMs measurements from two institutions was conducted. The prediction model was developed in the primary cohort that consisted of 1964 participants. Best subset regression was applied to select the most useful predictors from the primary dataset. The performance of the nomogram was evaluated with respect to its calibration, discrimination, and clinical usefulness. External validation was performed in an independent validation cohort of 1310 consecutive CRC patients. FINDINGS: Among the ten simplified clinicopathological features, seven variables were selected as the best subset of risk factors to develop pathology-based model, including age, tumour diameters, histology, tumour location, perineural invasion, the number of sampled lymph nodes (LNs) and positive LNs. The model showed good calibration and discrimination, with an AUC of 0.756 (95% CI, 0.722 to 0.789) in the primary cohort and 0.754 (95% CI, 0.715 to 0.793) in the validation cohort. After the addition of CEA and CA 72-4, the performance of pathology-based model was significantly improved in in both the primary cohort (AUC: 0.805 (0.774-0.835) vs. 0.756 (0.722-0.789), P < 0.001) and validation cohort (AUC: 0.796 (0.758-0.835) vs. 0.754 (0.715-0.793), P < 0.001). The results of decision curve analysis revealed that using our models to predict the status of MMR would add more benefit than either the detect-all-patients scheme or the detect-none scheme. INTERPRETATION: The models based on simplified clinicopathological features alone or in combination with STMs can be conveniently used to facilitate the postoperative individualized prediction of MMR status in CRC patients.
format Online
Article
Text
id pubmed-7578682
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75786822020-10-23 Development and validation of MMR prediction model based on simplified clinicopathological features and serum tumour markers Cao, Yinghao Peng, Tao Li, Han Yang, Ming Wu, Liang Zhou, Zili Zhang, Xudan Han, Shengbo Bao, Haijun Cai, Kailin Zhao, Ning EBioMedicine Research Paper BACKGROUND: Although simplified clinicopathological features and serum tumour markers (STMs) were reported to be associated with the status of mismatch repair (MMR) in colorectal cancer (CRC) patients, their predictive value alone or in combination for MMR status remains unknown. METHODS: A retrospective analysis of 3274 participants with MMR testing and STMs measurements from two institutions was conducted. The prediction model was developed in the primary cohort that consisted of 1964 participants. Best subset regression was applied to select the most useful predictors from the primary dataset. The performance of the nomogram was evaluated with respect to its calibration, discrimination, and clinical usefulness. External validation was performed in an independent validation cohort of 1310 consecutive CRC patients. FINDINGS: Among the ten simplified clinicopathological features, seven variables were selected as the best subset of risk factors to develop pathology-based model, including age, tumour diameters, histology, tumour location, perineural invasion, the number of sampled lymph nodes (LNs) and positive LNs. The model showed good calibration and discrimination, with an AUC of 0.756 (95% CI, 0.722 to 0.789) in the primary cohort and 0.754 (95% CI, 0.715 to 0.793) in the validation cohort. After the addition of CEA and CA 72-4, the performance of pathology-based model was significantly improved in in both the primary cohort (AUC: 0.805 (0.774-0.835) vs. 0.756 (0.722-0.789), P < 0.001) and validation cohort (AUC: 0.796 (0.758-0.835) vs. 0.754 (0.715-0.793), P < 0.001). The results of decision curve analysis revealed that using our models to predict the status of MMR would add more benefit than either the detect-all-patients scheme or the detect-none scheme. INTERPRETATION: The models based on simplified clinicopathological features alone or in combination with STMs can be conveniently used to facilitate the postoperative individualized prediction of MMR status in CRC patients. Elsevier 2020-10-20 /pmc/articles/PMC7578682/ /pubmed/33096478 http://dx.doi.org/10.1016/j.ebiom.2020.103060 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Cao, Yinghao
Peng, Tao
Li, Han
Yang, Ming
Wu, Liang
Zhou, Zili
Zhang, Xudan
Han, Shengbo
Bao, Haijun
Cai, Kailin
Zhao, Ning
Development and validation of MMR prediction model based on simplified clinicopathological features and serum tumour markers
title Development and validation of MMR prediction model based on simplified clinicopathological features and serum tumour markers
title_full Development and validation of MMR prediction model based on simplified clinicopathological features and serum tumour markers
title_fullStr Development and validation of MMR prediction model based on simplified clinicopathological features and serum tumour markers
title_full_unstemmed Development and validation of MMR prediction model based on simplified clinicopathological features and serum tumour markers
title_short Development and validation of MMR prediction model based on simplified clinicopathological features and serum tumour markers
title_sort development and validation of mmr prediction model based on simplified clinicopathological features and serum tumour markers
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578682/
https://www.ncbi.nlm.nih.gov/pubmed/33096478
http://dx.doi.org/10.1016/j.ebiom.2020.103060
work_keys_str_mv AT caoyinghao developmentandvalidationofmmrpredictionmodelbasedonsimplifiedclinicopathologicalfeaturesandserumtumourmarkers
AT pengtao developmentandvalidationofmmrpredictionmodelbasedonsimplifiedclinicopathologicalfeaturesandserumtumourmarkers
AT lihan developmentandvalidationofmmrpredictionmodelbasedonsimplifiedclinicopathologicalfeaturesandserumtumourmarkers
AT yangming developmentandvalidationofmmrpredictionmodelbasedonsimplifiedclinicopathologicalfeaturesandserumtumourmarkers
AT wuliang developmentandvalidationofmmrpredictionmodelbasedonsimplifiedclinicopathologicalfeaturesandserumtumourmarkers
AT zhouzili developmentandvalidationofmmrpredictionmodelbasedonsimplifiedclinicopathologicalfeaturesandserumtumourmarkers
AT zhangxudan developmentandvalidationofmmrpredictionmodelbasedonsimplifiedclinicopathologicalfeaturesandserumtumourmarkers
AT hanshengbo developmentandvalidationofmmrpredictionmodelbasedonsimplifiedclinicopathologicalfeaturesandserumtumourmarkers
AT baohaijun developmentandvalidationofmmrpredictionmodelbasedonsimplifiedclinicopathologicalfeaturesandserumtumourmarkers
AT caikailin developmentandvalidationofmmrpredictionmodelbasedonsimplifiedclinicopathologicalfeaturesandserumtumourmarkers
AT zhaoning developmentandvalidationofmmrpredictionmodelbasedonsimplifiedclinicopathologicalfeaturesandserumtumourmarkers